Bank Of New York Mellon Corp 89bio, Inc. Transaction History
Bank Of New York Mellon Corp
- $557 Trillion
- Q3 2025
A detailed history of Bank Of New York Mellon Corp transactions in 89bio, Inc. stock. As of the latest transaction made, Bank Of New York Mellon Corp holds 349,679 shares of ETNB stock, worth $5.19 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
349,679
Previous 349,572
0.03%
Holding current value
$5.19 Million
Previous $3.43 Billion
49.74%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding ETNB
# of Institutions
236Shares Held
156MCall Options Held
774KPut Options Held
6.48M-
Ra Capital Management, L.P. Boston, MA19.9MShares$295 Million5.01% of portfolio
-
Pentwater Capital Management LP Naples, FL11.8MShares$174 Million1.08% of portfolio
-
Deep Track Capital, LP Greenwich, CT9.36MShares$139 Million4.33% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA9.1MShares$135 Million0.22% of portfolio
-
Suvretta Capital Management, LLC New York, NY8.28MShares$123 Million3.65% of portfolio
About 89bio, Inc.
- Ticker ETNB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,484,500
- Market Cap $690M
- Description
- 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...